La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Neuren Pharmaceuticals Salute del bilancio
Salute finanziaria criteri di controllo 6/6
Neuren Pharmaceuticals ha un patrimonio netto totale di A$205.2M e un debito totale di A$0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente A$248.0M e A$42.8M. L'EBIT di Neuren Pharmaceuticals è A$199.2M rendendo il suo rapporto di copertura degli interessi -35. Ha liquidità e investimenti a breve termine pari a A$228.5M.
Informazioni chiave
0%
Rapporto debito/patrimonio netto
AU$0
Debito
| Indice di copertura degli interessi | -14.3x |
| Contanti | AU$213.17m |
| Patrimonio netto | AU$219.15m |
| Totale passività | AU$9.00m |
| Totale attività | AU$228.15m |
Aggiornamenti recenti sulla salute finanziaria
Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business
Jan 07
We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
Sep 06Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth
May 31We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn
Feb 03Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation
Aug 06We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
May 05Recent updates
Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models
Aug 29Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now
Aug 14Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today
May 31Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely
May 03An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued
Apr 01Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically
Mar 05Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors
Mar 02Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors
Dec 18Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues
Sep 02Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Aug 31This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year
Mar 03Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business
Jan 07We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
Sep 06Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth
May 31We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn
Feb 03Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation
Aug 06We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
May 05Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)
Feb 19Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?
Jan 04
Analisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( A$247.2M ) di NEU superano le sue passività a breve termine ( A$42.8M ).
Passività a lungo termine: Le attività a breve termine di NEU ( A$228.0M ) superano le sue passività a lungo termine ( A$29.0K ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: NEU è esente da debiti.
Riduzione del debito: NEU non ha avuto debiti negli ultimi 5 anni.
Copertura del debito: NEU non ha debiti, pertanto non deve essere coperto dal flusso di cassa operativo.
Copertura degli interessi: NEU non ha debiti, pertanto la copertura dei pagamenti degli interessi non è un problema.